Efficacy and safety of vitamin D3 in patients with diabetic nephropathy: A meta-analysis of randomized controlled trials

Chinese Medical Journal

Volumn 127, Issue 15, 2014, Pages 2837-2843

  Zhao, Jun Yu ^a   Dong, Jian Jun ^b   Wang, Hai Peng ^c   Shang, Hong Xia ^a   Zhang, Dong Mei ^b   Liao, Lin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; Meta analysis; Randomized controlled trials; Systemic review

Indexed keywords

ALFACALCIDOL; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CALCITRIOL; COLECALCIFEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; HEMOGLOBIN A1C; IRBESARTAN; PARICALCITOL; TELMISARTAN; VALSARTAN;

ARTICLE; BLOOD PRESSURE MONITORING; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL DISEASE; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; HYPOTENSION; META ANALYSIS; MICROALBUMINURIA; PROTEINURIA; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RISK FACTOR; SYSTEMATIC REVIEW; BLOOD PRESSURE; DIABETIC NEPHROPATHIES; DRUG EFFECTS;

BLOOD PRESSURE; CHOLECALCIFEROL; DIABETIC NEPHROPATHIES; HUMANS; PROTEINURIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84905576125     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20140792     Document Type: Article

References (56)

1. Krairittichai U, Mahannopkul R, Bunnag S. An open label, randomized controlled study of oral calcitriol for the treatment of proteinuria in patients with diabetic kidney disease. J Med Assoc Thai 2012; 95: S41-S47.
2. Huang Y, Yu H, Lu J, Guo K, Zhang L, Bao Y, et al. Oral supplementation with cholecalciferol 800 IU ameliorates albuminuria in Chinese type 2 diabetic patients with nephropathy. PLoS One 2012; 7: e50510.
3. Bonakdaran S, Hami M, Hatefi A. The effects of calcitriol on albuminuria in patients with type-2 diabetes mellitus. Saudi J Kidney Dis Transpl 2012; 23: 1215-1220.
4. Ohara I, Tanimoto M, Gohda T, Yamazaki T, Hagiwara S, Murakoshi M, et al. Effect of combination therapy with angiotensin receptor blocker and 1, 25-dihydroxyvitamin D(3) in type 2 diabetic nephropathy in KK-A(y)/Ta mice. Nephron Exp Nephrol 2011; 117: e124-e132.
5. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376: 1543-1551.
6. Kim MJ, Frankel AH, Donaldson M, Darch SJ, Pusey CD, Hill PD, et al. Oral cholecalciferol decreases albuminuria and urinary TGF-beta1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. Kidney Int 2011; 80: 851-860.
7. Li YC. Vitamin D and diabetic nephropathy. Curr Diab Rep 2008; 8: 464-469.
8. Lavoie JL, Sigmund CD. Minireview: overview of the reninangiotensin system-an endocrine and paracrine system. Endocrinology 2003; 144: 2179-2183.
9. Chan JC, Ko GT, Leung DH, Cheung RC, Cheung MY, So WY, et al. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000; 57: 590-600.
10. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1, 25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-238.
11. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Review Vitamin D: a negative endocrine regulator of the reninangiotensin system and blood pressure. J Steroid Biochem Mol Biol 2004; 89-90: 387-392.
12. Guan X, Yang H, Zhang W, Wang H, Liao L. Vitamin D receptor and its protective role in diabetic nephropathy. Chin Med J 2014; 127: 365-369.
13. Zhang Z, Sun L, Wang Y, Ning G, Minto AW, Kong J, et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 2008; 73: 163-171.
14. Weil EJ, Lemley KV, Mason CC, Yee B, Jones LI, Blouch K, et al. Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. Kidney Int 2012; 82: 1010-1017.
15. Lim AKH, Tesch GH. Inflammation in diabetic nephropathy. Mediators Inflamm 2012; doi: 10. 1155/2012/146154.
16. Tan X, Wen X, Liu Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NFkappa B signaling. J Am Soc Nephrol 2008; l19: 1741-1752.
17. Zhang Z, Yuan W, Sun L, Szeto FL, Wong KE, Li X, et al. 1, 25-Dihydroxyvitamin D(3) targeting of NF kappa B suppresses high glucose induced MCP-1 expression in mesangial cells. Kidney Int 2007; 72: 193-201.
18. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006; 17: 3382-3393.
19. Muller K, Haahr PM, Diamant M, Rieneck K, Kharazmi A, Bendtzen K. 1, 25-Dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the posttranscriptional level. Cytokine 1992; 4: 506-512.
20. Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I, Galaktidou G. Paricalcitol reduces basal and lipopolysaccharide-induced (LPS) TNF-alpha and IL-8 production by human peripheral blood mononuclear cells. Int Urol Nephrol 2010; 42: 181-185.
21. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008; 52: 249-255.
22. Ahmadi N, Mortazavi M, Iraj B, Askari G. Whether vitamin D3 is effective in reducing proteinuria in type 2 diabetic patients? J Res Med Sci 2013; 18: 374-377.
23. Xu P, Chen XH. Effect of combined therapy with benazepril and alfacalcidol in patients with diabetic nephropathy (in Chinese). Chin J Gen Prac 2010; 13: 3268-3270.
24. Xu P, Zhang H. Effect of alfacalcidol on microinflammation in the patients with type 2 diabetic nephropathy (in Chinese). Chin J Gen Prac 2011; 14: 1649-1651.
25. Xue YH, Li CX. Effect of combined therapy with benazepril and rocaltrol in DN patients (in Chinese). Med Information 2011; 9: 4403-4404.
26. Zhou B, Zhao Y. Curative effect of calcitriol combined with irbesartan in the treatment of diabetic nephropathy (in Chinese). China Med Herald 2013; 10: 86-91.
27. Ian deBoer, University of Washington. Randomized controlled trial of vitamin D3 in diabetic kidney disease. ClinicalTrials. gov Identifier: NCT00552409.
28. Ding H, Zhan C, Wang ZQ, Li YN, Min R. Effect of calcitriol on albuminuria and high-sensitivity C-reactive protein in patients with diabetic nephropathy (in Chinese). Shandong Med J 2011; 51: 80-81.
29. Guan HB, Huang H, Heng WM, He KP, Wang B. Effect of combined therapy with calcitriol and telmisartan in patients with diabetic nephropathy (in Chinese). Guangdong Med J 2012; 33: 2488-2490.
30. Li MJ, Xiao F, Zhang XY. Combined treatment with calcitriol and valsartan for patients with diabetic kidney disease (in Chinese). Med Information 2013; 26: 143-144.
31. Lu Y, Zhang MY. Effect of combined therapy with calcitriol and fosinopril on serum and urine MCP-1 in patients with type 2 diabetic nephropathy (in Chinese). Chin J Mod Drug 2011; 5: 155-156.
32. Ni J, Xu P, Zhang J, Zhang L, Fang Y. Clinical observation of the therapeutic effect of calcitriol combined with fosinopril on type 2 diabetic nephropathy (in Chinese). Pract Geriatr 2013; 27: 119-122.
33. Pang XH. Observation of clinical effects of calcitriol combined with telmisartan on diabetic nephropathy (in Chinese). China Modern Doctor 2013; 51: 52-54.
34. Shui GX, Yin X, Sang D, Zou F, He D, Lu ZF, et al. Randomized controlled trials of 1, 25(OH)2D3 on proteinuria in patients with diabetic nephropathy. CJITWN 2012; 13: 429-431.
35. Zheng XZ, Xu YH. Observation of clinical effect of calcitriol on diabetic nephropathy (in Chinese). Strait Pharmaceut J 2013; 25: 133-134.
36. Zhou XH, Liu SY, Li YF, Qin YX, Zheng LL. Effect of combined therapy with alfacacidol and telmisartan on diabetic nephropathy in early stage (in Chinese). Chin J Diabetes 2012; 20: 675-677.
37. Zhou YJ, Xu H. Observation of clinical effect of combined therapy with 1, 25-(OH)2D3 and ARB in early stage of diabetic nephropathy (in Chinese). CJITWN 2013; 14: 60-62.
38. Zhu HY, Zhang D, Geng WJ, Liu MY, Xie YS, Chen XM. Effect of 1, 25-dihydroxyvitamin D3 on serum proinflammatory factors (in Chinese). J Chin Prac Diagn Ther 2012; 26: 12-14.
39. Sanchez-Niño MD, Bozic M, Córdoba-Lanús E, Valcheva P, Gracia O, Ibarz M, et al. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am J Physiol Renal Physiol 2012; 302: F647-F657.
40. Deb DK, Chen Y, Zhang Z, Zhang Y, Szeto FL, Wong KE, et al. 1, 25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-(kappa) B pathway. Am J Physiol Renal Physiol 2009; 296: F1212-F1218.
41. Yang M, Shen Z, Chen D, Gan H, Shen Q, Yang B, et al. Effects of 1, 25-(OH)(2)D(3) on the expressions of vitamin D receptor, STAT5 and cytoskeletal rearrangement in human monocytes incubated with sera from type 2 diabetes patients and diabetic nephropathy patients with uremia. Inflamm Res 2012; 61: 511-520.
42. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calciumindependent and 1, 25(OH)(2)D(3)-dependent regulation of the reninangiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 2008; 74: 170-179.
43. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005; 288: E125-E132.
44. Szeto FL, Reardon CA, Yoon D, Wang Y, Wong KE, Chen Y, et al. Vitamin D receptor signaling inhibits atherosclerosis in mice. Mol Endocrinol 2012; 26: 1091-1101.
45. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, et al. Cardiac hypertrophy in vitamin D receptor knockoutmice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005; 288: E125-E132.
46. Gekle M, Knaus P, Nielsen R, Mildenberger S, Freudinger R, Wohlfarth V, et al. Transforming growth factor-beta1 reduces megalin-and cubilin-mediated endocytosis of albumin in proximal-tubule-derived opossum kidney cells. J Physiol 2003; 552: 471-481.
47. Russo LM, del Re E, Brown D, Lin HY. Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelior ation by soluble TGF-beta type I I r eceptor. Diabetes 2007; 56: 380-388.
48. Anderson RL, Ternes SB, Strand KA, Rowling MJ. Vitamin D homeostasis is compromised due to increased urinary excretion of the 25-hydroxycholecalciferol-vitamin D-binding protein complex in the Zucker diabetic fatty rat. Am J Physiol Endocrinol Metab 2010; 299: E959-E967.
49. Levi M, Wang XX, Choudhury D. Nuclear hormone receptors as therapeutic targets. Contrib Nephrol 2011; 170: 209-216.
50. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci U S A 2008; 105: 15896-15901.
51. Zehnder D, Quinkler M, Eardley KS, Bland R, Lepenies J, Hughes SV, et al. Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. Kidney Int 2008; 74: 1343-1353.
52. Panichi V, Migliori M, Taccola D, Filippi C, De Nisco L, Giovannini L, et al. Effects of 1, 25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int 2001; 60: 87-95.
53. Ha H, Yu MR, Choi YJ, Kitamura M, Lee HB. Role of high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expressionby mesangial cells. J Am Soc Nephrol 2002; 13: 894-902.
54. Li Y, Spataro BC, Yang J, Dai C, Liu Y. 1, 25-dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int 2005; 68: 1500-1510.
55. Kuhlmann A, Haas CS, Gross ML, Reulbach U, Holzinger M, Schwarz U, et al. 1, 25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004; 286: F526-F533.
56. Migliori M, Giovannini L, Panichi V, Filippi C, Taccola D, Origlia N, et al. Treatment with 1, 25-dihydroxyvitamin D3 preserves glomerular slit diaphragm-associated protein expression in experimental glomerulonephritis. Int J Immunopathol Pharmacol 2005; 18: 779-790.